Kiniksa Pharmaceuticals International (KNSA) Operating Income (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Operating Income came in at $27.2 million in Q2 2026, up 34.89% YoY from $20.2 million in Q2 2025, and down 7.08% on a QoQ basis from $29.3 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Operating Income (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Operating Income data on file, last reported at $27.2 million in Q2 2026.
- Quarterly Operating Income rose 34.89% year-over-year to $27.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $100.2 million (up 2140.22% YoY) and the FY2025 annual result came in at $77.2 million, up 269.28% from the prior year.
- Operating Income declined to $27.2 million in Q2 2026, from $29.3 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $46.4 million in Q3 2022 to a low of -$23.3 million in Q1 2022.
- A 5-year average of $4.0 million and a median of -$18000.0 in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income plunged 23925.93% — and 2025, when it surged 17330.77%.
- Tracing KNSA's Operating Income over 5 years: stood at $6.0 million in 2022, then plunged by 98.66% to $81000.0 in 2023, then sank by 23925.93% to -$19.3 million in 2024, then jumped by 202.43% to $19.8 million in 2025, then surged by 37.57% to $27.2 million in 2026.
- The last three Operating Income figures came in at $27.2 million (Q2 2026), $29.3 million (Q1 2026), and $19.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.57 Bn | 220.03 Mn | 27.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.19 Mn |
| Mar 31, 2026 | 29.27 Mn |
| Dec 31, 2025 | 19.77 Mn |
| Sep 30, 2025 | 24.02 Mn |
| Jun 30, 2025 | 20.16 Mn |
| Mar 31, 2025 | 13.27 Mn |
| Dec 31, 2024 | -19.30 Mn |
| Sep 30, 2024 | -9.66 Mn |
| Jun 30, 2024 | -117,000.00 |
| Mar 31, 2024 | -16.54 Mn |
| Dec 31, 2023 | 81,000.00 |
| Sep 30, 2023 | -10.93 Mn |
| Jun 30, 2023 | -3.15 Mn |
| Mar 31, 2023 | -11.20 Mn |
| Dec 31, 2022 | 6.05 Mn |
| Sep 30, 2022 | 46.41 Mn |
| Jun 30, 2022 | -19.37 Mn |
| Mar 31, 2022 | -23.32 Mn |
| Dec 31, 2021 | -36.13 Mn |
| Sep 30, 2021 | -30.67 Mn |